Lumicell
FDA announces acceptance and priority review of NDA for LUMISIGHT imagining agent for breast cancer
May 23, 2023Research and Development FDA, Lumicell, Oncology, breast cancer, oncology
Lumicell has announced that the US Food and Drug Administration (FDA) has accepted and granted priority review for the New …
Latest content
The evidence bar impacting UK medical cannabis access
November 6, 2026
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
